滨州医学院学报2025，Vol.48Issue(4)：366-370,5.DOI:10.19739/j.cnki.issn1001-9510.2025.04.006
恩度胸腔灌注联合鸦胆子油乳静滴治疗肺癌伴恶性胸腔积液的临床疗效
Observation of the clinical efficacy of Endostar combined with Brucea Javanica Oil Emulsion in the treatment of malignant pleural effusion of lung cancer
摘要
Abstract
Objective To investigate the clinical efficacy and safety of Endostar combined with Brucea Javanica Oil Emulsion in the treatment of malignant pleural effusion(MPE).Methods A total of 49 patients with lung cancer,who had malignant pleural effusion,were selected from August 2022 to August 2024 from Binzhou People's Hospital and Yangxin People's Hospital.The study was divided into two groups.A control study was adopted to set the treatment group and the control group.In group A,25 cases were treated with Endostar injection perfusion combined with intravenous infusion of Brucea Javanica Oil Emulsion,and in the control group,24 cases were treated with Endostar injection combined with cisplatin perfusion.Important data in both groups were collected for comparative analysis,including the disease control rate(DCR),the objective response rate(ORR),the ECOG physical status score,adverse reactions and blood tumor markers.Results Before the treatment,there were no signif-icant differences in ECOG scores between the study group and the control group.After the treatment,ECOG scores decreased,and physical state increased in both groups compared with before the treatment,but the differences were not statistically signifi-cant.Before the treatment,there was no significant difference in the levels of CYFRA21-1 associated with non-small cell lung cancer(NSCLC)between 2 groups;after the treatment,with the study group(7.06±1.70)VS the control group(7.25±1.88),the difference was not statistically significant;however,the levels of blood NSCLC-associated CYFRA21-1 in both groups were lower than before,and the difference was statistically significant(P＜0.05).In terms of efficacy,the ORR in group A was 68.0％(17/25),and the DCR was 88.0％(22/25);in group B,the ORR was 79.2％(19/24),and the DCR was 95.8％(23/24);there was no statistically significant difference in the two groups(x2=0.783,P=0.376;x2=0.230,P=0.632).Stratified analysis was performed for whether the ECOG score was greater than 2 points,whether the patients had undergone sys-temic chemotherapy in the past,whether the patients were older than 65 years old,whether the pleural effusion was treated for the first time and whether it was hemorrhagic,and the results showed that the ORR differences were statistically significant when the ECOG score was more than 2,and the short-term efficacy of the study group was higher than that of the control group.After the treatment,the main adverse reactions in both groups were leukopenia,fatigue,chest pain,nausea and vomiting,and so on.A-mong them,the nausea and vomiting,fatigue and chest pain were statistically significant difference(x2=4.864,P=0.027;x2=4.306,P=0.038;x2=3.984,P=0.046).Conclusion Endostar,when combined with Brucea Javanica Oil Emulsion Injection(BJOEI),demonstrates noteworthy efficacy in treating malignant pleural effusion,and its tolerability is good for impro-ving physical condition of patients,especially for the elderly with poor physical condition(ECOG greater than 2 points),so it can be recommended for clinical application.关键词
恶性胸腔积液/灌注治疗/血管内皮抑制素注射液/鸦胆子油乳/肺癌Key words
malignant pleural effusion/perfusion therapy/Endostar/Brucea Javanica Oil Emulsion/lung cancer分类
医药卫生引用本文复制引用
王鹏,张彩霞,李莉..恩度胸腔灌注联合鸦胆子油乳静滴治疗肺癌伴恶性胸腔积液的临床疗效[J].滨州医学院学报,2025,48(4):366-370,5.基金项目
山东省医务职工科技创新计划联合立项项目(SDYWZGKCJHLH202207) （SDYWZGKCJHLH202207）
山东省医学会临床科研资金-齐鲁专项(YXH2022ZX02034) （YXH2022ZX02034）
